← Storyflo·storyflo · health and longevity· health
Health
Daily Health & Wellness Brief · September 8th
storyflo · health and longevity
Sep 8, 2026 · 3 min listen · Last updated September 8, 2026
From storyflo. This is your daily audio brief. Hey, it's Chloe. September 8th. Ten stories — one trial, three reviews, six takes you can actually use. Let's get into it. First, from Endpoints Pharma. Novartis sinks after second disastrous trial failure, this time of Avidity-acquired drug.
Listen · storyflo · health and longevity
Daily Health & Wellness Brief · September 8th
0:00-3:11
Pick your daily storyteller
Subscribe to match with Theo, Jessica, Chloe, Mason, Brock — your voice, every brief.
Audio pre-rendered by Storyflo · cached + delivered from the edge
Novartis sinks after second disastrous trial failure, this time of Avidity-acquired drug
Novartis faced a significant setback after the failure of a drug acquired from Avidity. This marks their second trial failure in a short period, raising concerns about their pipeline and ability to deliver effective treatments. The specific details of the trial results haven't been disclosed, but the implications for Novartis's stock and investor confidence are clear. This kind of news can shake up the market, especially for a company that's already navigating challenges. Investors will likely be keeping a close eye on how Novartis plans to address these issues moving forward. It's a tough spot for them right now.
STAT+: Neuromuscular drug from Novartis fails in key study, adding to pressure on company
Hey! So, I wanted to tell you about this drug Novartis was testing for a rare muscle-wasting disease called myotonic dystrophy type 1, or DM1. It's a condition that makes muscles stiff and weak.
So, the big news is that this drug, del-desiran, didn't actually work in a major study. They were looking to see if it could help people relax their hands better after squeezing, which is a way to measure muscle function. Unfortunately, it didn't do any better than a placebo, which is kind of a bummer.
This is actually the second time in a short period that one of their big drug trials has failed. It definitely puts some pressure on Novartis, especially because they're facing some patent expirations soon. They did have a win with a multiple sclerosis drug recently, so it's not all bad news, but this is a pretty significant setback for their pipeline.
Leslie hosted a delightful Indian dinner inspired by a recent trip to Houston. She recreated a coconut stew she loved, but opted for a quicker shrimp dish called Yerra Moolee instead. To enhance it, she added roasted zucchini and charred Romano beans, although she forgot the ginger, which she thought would have elevated the dish even more.
The evening started with a refreshing non-alcoholic drink, a Sparkling Lime Drink, reminiscent of a favorite from her travels in India. She also served spiced cashews, which were easy to make and paired well with both the drink and gin & tonics.
For the main course, she prepared charred baby eggplants, coconut milk shrimp with the added veggies, and saag made from a mix of greens. Despite some last-minute challenges, like discovering bugs in her basmati rice, Leslie managed to create a warm and inviting meal for her friends. She reflected on how planning ahead could have made things smoother. Overall, it was a lovely evening filled with good food and laughter.
The article captures a lovely day filled with simple joys. It starts with a drive through New England, where the first signs of fall are appearing with vibrant leaves. There’s a delightful mention of enjoying maple butter on gluten-free toast, which sounds absolutely delicious. The day wraps up with a visit to a charming neighborhood garden center, where the author and their son pick out some fresh houseplants. It’s a reminder of how small moments, like appreciating nature and sharing food, can bring happiness. Now, it’s your turn to reflect on three good things in your life.
US Representative Scrutinizes Practices of IDR Entities
Rep. Frank Pallone is asking six independent dispute‑resolution firms to hand over their arbitration data, because lawmakers are worried those companies might be inflating costs under the No Surprises Act. He’s looking for the number of cases they’ve handled, the average award amounts, and how often they side with providers versus patients.
The request comes after a handful of reports suggested that some arbitrators are consistently ruling in favor of hospitals, which could be driving higher out‑of‑pocket bills. Pallone wants to see whether the firms’ practices line up with the law’s intent to keep surprise bills low.
If the data show a pattern of large, provider‑biased awards, it could prompt tighter oversight or new rules for how these arbitrations are run. For now, the firms have a short window to comply, and the committee will decide what, if any, policy changes are needed.
Send this story to anyone — or drop the embed into a blog post, Substack, Notion page. Every play sends rev-share back to storyflo · health and longevity.